Cyclerion fails sickle cell test, prompting pivot to CNS disease

Cyclerion Therapeutics has stopped development of olinciguat in sickle cell disease after getting a look at data from a phase 2 trial. The setback prompted Cyclerion to switch its focus to IW-6463 and the treatment of diseases of the central nervous system.